JLJosé María Serra López-Matencio

José María Serra López-Matencio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


José María Serra López-Matencio has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Management of local and delayed cutaneous hypersensitivity reactions to anti-CGRP antibodies: implications for continuing treatment

    by Celia Romero del Rincon, Paula Panos Basterra, Patricia Heredia-Rodriguez, José María Serra López-Matencio, Francisco Vega, Ana Beatriz Gago-Veiga

    Background Delayed local skin reactions—appearing 24 to 48 h after subcutaneous injection—such as erythema, induration, pruritus, and pain, have been reported in patients receiving anti-Calcitonin Gene-Related Peptide monoclonal antibodies (anti-CGRP mAbs). Although typically mild to moderate in severity, these reactions can occasionally be intense and may lead to treatment discontinuation due to concerns from either the clinician or the patient. Measures and intervention We developed a structured tolerance protocol consisting of four steps: administration of an oral antihistamine and topical corticosteroid as pre-injection medication, prioritization of the abdominal area for subcutaneous monoclonal antibody administration, use of oral non-steroidal antinflammatory drugs (NSAID), cold compress post-injection, and continued topical and oral treatment as needed. Outcomes This protocol was applied to three patients who had previously experienced delayed skin reactions to erenumab, galcanezumab, or fremanezumab. With the use of the protocol, all three were able to continue treatment, with symptoms either markedly reduced or fully resolved. Conclusion This protocol offers a practical and effective approach to managing local skin reactions, promoting the continued use of anti-CGRP mAbs for migraine. Its simplicity facilitates implementation even in home-based care settings.

  • Open Access

    Effectiveness and Safety of the COVID-19 Vaccine in Patients with Rheumatoid Arthritis in a Real-World Setting

    by María Torres-Rufas, Esther F. Vicente-Rabaneda, Laura Cardeñoso, Ainhoa Gutierrez, David A. Bong, Cristina Valero-Martínez, José M. Serra López-Matencio, Rosario García-Vicuña, Miguel A. González-Gay, Isidoro González-Álvaro, et al.

    Novel mechanisms of COVID-19 vaccines raised concern about their potential immunogenicity in patients with rheumatoid arthritis (RA) undergoing immunomodulatory treatments. We designed a retrospective single-center study to investigate their effectiveness and safety in this population, analyzing data from the first vaccination program (December 2020–October 2021). Inclusion criteria were availability of post-vaccination serology and a minimum subsequent follow-up of 6 months. Binding antibody units (BAU/mL) ≥ 7.1 defined an adequate serological response. Post-vaccine COVID-19 incidence and its timing since vaccination, adverse events (AEs), and RA flares were recorded. Adjusted logistic and linear multivariate regression analyses were carried out to identify factors associated with vaccine response. We included 118 patients (87.2% women, age 65.4 ± 11.6 years, evolution 12.0 ± 9.6 years), of whom 95.8% had a complete vaccination schedule. Adequate humoral immunogenicity was achieved in 88.1% of patients and was associated with previous COVID-19 and mRNA vaccines, whereas smoking, aCCP, age, and DMARDs exerted a negative impact. Post-vaccine COVID-19 occurred in 18.6% of patients, a median of 6.5 months after vaccination. Vaccine AE (19.5%) and RA flares (1.7%) were mostly mild and inversely associated with age. Our results suggest that COVID-19 vaccines induce adequate humoral immunogenicity, with an acceptable safety profile in RA patients.


  • Open Access

    Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis

    by Pedro Martínez-Fleta, Esther F. Vicente-Rabaneda, Ana Triguero-Martínez, Emilia Roy-Vallejo, Miren Uriarte-Ecenarro, Francisco Gutiérrez-Rodríguez, Patricia Quiroga-Colina, Ana Romero-Robles, Nuria Montes, Noelia García-Castañeda, et al.

    B and T cell responses were evaluated in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) after 1 or 2 weeks of methotrexate (MTX) withdrawal following each COVID-19 vaccine dose and compared with those who maintained MTX. Adult RA and PsA patients treated with MTX were recruited and randomly assigned to 3 groups: MTX-maintenance (n = 72), MTX-withdrawal for 1 week (n = 71) or MTX-withdrawal for 2 weeks (n = 73). Specific antibodies to several SARS-CoV-2 antigens and interferon (IFN)-γ and interleukin (IL)-21 responses were assessed. MTX withdrawal in patients without previous COVID-19 was associated with higher levels of anti-RBD IgG and neutralising antibodies, especially in the 2-week withdrawal group and with higher IFN-γ secretion upon stimulation with pools of SARS-CoV-2 S peptides. No increment of RA/PsA relapses was detected across groups. Our data indicate that two-week MTX interruption following COVID-19 vaccination in patients with RA or PsA improves humoral and cellular immune responses.


  • Open Access

    Effectiveness and Safety of the COVID-19 Vaccine in Patients With Rheumatoid Arthritis in a Real-World Setting

    by María Torres-Rufas, Esther F. Vicente-Rabaneda, Laura Cardeñoso, Ainhoa Gutiérrez-Cobos, Cristina Valero-Martínez, José M. Serra López-Matencio, Rosario García-Vicuña, Miguel A. González-Gay, Isidoro González-Álvaro, Santos Castañeda

    Background: To describe the effectiveness and safety of COVID-19 vaccine in a series of patients with rheumatoid arthritis (RA). Methods: Retrospective single-center study of RA patients, fulfilling the ACR 1987 or ACR/EULAR 2010 classification criteria, that received first COVID-19 vaccine between December 2020 and October 2021, had post-vaccination serology and subsequent follow-up of at least 6 months in a university hospital. Vaccine effectiveness was evaluated by the serological response and the incidence of post-vaccine COVID-19, and safety by the incidence of adverse events (AE) and RA flares. Adjusted logistic and linear multivariate regression analyses were carried out with Stata® to identify factors associated with vaccine response. Results: We included 118 patients with RA (87.2% women, age 65.4±11.6 years, evolution 12.0±9.6 years). 95.8% received complete vaccination schedule. Most patients (88.1%) developed adequate humoral immunogenicity, and the degree of serological response was significantly related to younger age and previous COVID-19 infection. After vaccination, 18.6% presented mild SARS-CoV-2 infection. Vaccine AE (19.5%) were mostly mild and inversely associated with age (OR 0.95). RA flares were anecdotal (1.7%) and inversely related to age (OR 0.95). Conclusion: Our results suggest that COVID-19 vaccine induces adequate humoral immunogenicity, with an acceptable safety profile in RA patients.


  • Open Access

    COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases

    by José M. Serra López-Matencio, Esther F. Vicente-Rabaneda, Estefanía Alañón, Ainhoa Aranguren Oyarzabal, Pedro Martínez Fleta, Santos Castañeda

    The COVID-19 vaccination program has probably been the most complex and extensive project in history until now, which has been a challenge for all the people involved in the planning and management of this program. Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy have required special attention, not only because of the particular haste in carrying out the process but also because of the uncertainty regarding their response to the vaccines. We now have strong scientific evidence that supports the hypothesis that immunosuppressive therapy inhibits the humoral response to vaccines against other infectious agents, such as influenza, pneumococcus and hepatitis B. This has led to the hypothesis that the same could happen with the COVID-19 vaccine. Several studies have therefore already been carried out in this area, suggesting that temporarily discontinuing the administration of methotrexate for 2 weeks post-vaccination could improve the vaccine response, and other studies with various immunosuppressive drugs are in the same line. However, the fact of withholding or interrupting immunosuppressive therapy when dealing with COVID-19 vaccination remains unclear. On this basis, our article tries to compile the information available on the effect of immunosuppressant agents on COVID-19 vaccine responses in patients with IMIDs and proposes an algorithm for the management of these patients.


  • Open Access

    Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic

    by José M. Serra López-Matencio, Manuel Gómez, Esther F. Vicente-Rabaneda, Miguel A. González-Gay, Julio Ancochea, Santos Castañeda

    The discovery of antifibrotic agents have resulted in advances in the therapeutic management of idiopathic pulmonary fibrosis (IPF). Currently, nintedanib and pirfenidone have become the basis of IPF therapy based on the results of large randomized clinical trials showing their safety and efficacy in reducing disease advancement. However, the goal of completely halting disease progress has not been reached yet. Administering nintedanib with add-on pirfenidone is supposed to enhance the therapeutic benefit by simultaneously acting on two different pathogenic pathways. All this becomes more important in the context of the ongoing global pandemic of coronavirus disease 2019 (COVID-19) because of the fibrotic consequences following SARS-CoV-2 infection in some patients. However, little information is available about their drug–drug interaction, which is important mainly in polymedicated patients. The aim of this review is to describe the current management of progressive fibrosing interstitial lung diseases (PF-ILDs) in general and of IPF in particular, focusing on the pharmacokinetic drug-drug interactions between these two drugs and their relationship with other medications in patients with IPF.


  • Fármacos biosimilares: un nuevo escenario en las terapias biológicas

    by José M. Serra López-Matencio, Alberto Morell Baladrón, Santos Castañeda